ArticleDiscover oncology2026
Production of monoclonal antibodies (mAbs) against oralcarcinoma & its bioconjugation with solid lipid nanoparticles (SLN) for drug delivery.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This preliminary study explores a dual strategy of augmenting anticancer therapy with Carboplatin-loaded solid lipid nanoparticles (SLNs) alongside antigen-specific antibodies through immunization of KB oral carcinoma cells. KB and Sp2/01 myeloma cells were cultured and assessed for viability. Female Balb/c mice were immunized with KB cells, resulting in significant weight gainand spleen enlargement, suggesting immune activation. Enzyme-linked immunosorbent assay (ELISA) confirmed the production of antigen-specific antibodies, as indicated by an increase in absorbance at a 1:1000 serum dilution. Splenocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG), with optimal hybridoma generation achieved in the third trial. SLNs were formulated by the microemulsion method, which exhibited favourable physicochemical properties (particle size: 144.57 nm, PDI: 0.261, zeta potential: -32 mV). Cytotoxicity assays revealed time- and dose-dependent cytotoxic effects against oral squamous cell carcinoma (OSCC), with SLNs demonstrating greater potency compared to free Carboplatin. These findings underscore the promise of SLNs in cancer therapy and the generation of KB cell-targeting antibodies using hybridoma technology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.